文献速递心脑血管急症复苏、休克与脓毒症

肾上腺素给药途径对导管室内心搏骤停急性心肌梗死患者影响的前瞻性观察研究(iCPR研究)

A prospective observational study on impact of epinephrine administration route on acute myocardial infarction patients with cardiac arrest in the catheterization laboratory (iCPR study).
PubMed 文献 · Crit Care · 2022-12-20
一句话结论导管室内急性心肌梗死心搏骤停患者中,中心静脉或冠脉内给予肾上腺素较外周静脉与更高的ROSC率及更好神经预后相关,冠脉内途径与更高支架血栓风险相关。

该前瞻性两中心试点队列研究纳入158例在经皮冠状动脉介入治疗期间于导管室内发生心搏骤停的急性心肌梗死患者,比较外周静脉、中心静脉和冠脉内三种肾上腺素给药途径的结局。结果示外周静脉途径与更低的ROSC率相关(OR=0.14,95%CI=0.05-0.36,p<0.0001),中心静脉与冠脉内途径间无差异(p=0.9343);冠脉内途径支架血栓风险显著更高(冠脉内vs外周静脉OR=4.6,95%CI=1.5-14.3,p=0.0094;冠脉内vs中心静脉OR=6.0,95%CI=1.9-19.2,p=0.0025)。中心静脉和冠脉内途径ROSC后神经预后优于外周静脉。

要点

  • 导管室内急性心肌梗死心搏骤停患者中,外周静脉给予肾上腺素与更低的ROSC率相关(OR=0.14,95%CI=0.05-0.36,p<0.0001),中心静脉与冠脉内途径间无差异(p=0.9343)。
  • 冠脉内给予肾上腺素与显著更高的支架血栓风险相关:冠脉内vs外周静脉OR=4.6(95%CI=1.5-14.3,p=0.0094),冠脉内vs中心静脉OR=6.0(95%CI=1.9-19.2,p=0.0025)。
  • 中心静脉和冠脉内途径给药后ROSC神经预后优于外周静脉途径。
  • 研究纳入158例,中心静脉、冠脉内、外周静脉组分别为48例(30.4%)、50例(31.6%)、60例(38.0%)。

适用人群与场景

  • 在经皮冠状动脉介入治疗期间于导管室内发生心搏骤停的急性心肌梗死患者,前瞻性两中心试点队列研究纳入。

处置流程与药物剂量

  • 肾上腺素给药途径分为外周静脉、中心静脉和冠脉内三种,研究比较三种途径的结局。

研究设计与关键结果

  • 前瞻性两中心试点队列研究纳入158例,中心静脉、冠脉内、外周静脉组分别为48例(30.4%)、50例(31.6%)、60例(38.0%)。
  • 外周静脉给予肾上腺素与更低的ROSC率相关(OR=0.14,95%CI=0.05-0.36,p<0.0001),中心静脉与冠脉内途径间无差异(p=0.9343)。
  • 冠脉内途径支架血栓风险显著更高:冠脉内vs外周静脉OR=4.6(95%CI=1.5-14.3,p=0.0094);冠脉内vs中心静脉OR=6.0(95%CI=1.9-19.2,p=0.0025)。
  • 中心静脉和冠脉内途径的ROSC后神经预后优于外周静脉途径。

证据类型、等级与局限

  • 证据类型:前瞻性两中心试点队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与外周静脉给药相比,中心静脉和冠脉内给予肾上腺素与更高的ROSC率和更好的神经预后相关;冠脉内给药与更高的支架血栓风险相关。
  • 试验注册号:NCT05253937。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Epinephrine is routinely utilized in cardiac arrest; however, it is unclear if the route of administration affects outcomes in acute myocardial infarction patients with cardiac arrest.

OBJECTIVES: To compare the efficacy of epinephrine administered via the peripheral intravenous (IV), central IV, and intracoronary (IC) routes.

METHODS: Prospective two-center pilot cohort study of acute myocardial infarction patients who suffered cardiac arrest in the cardiac catheterization laboratory during percutaneous coronary intervention. We compared the outcomes of patients who received epinephrine via peripheral IV, central IV, or IC.

RESULTS: 158 participants were enrolled, 48 (30.4%), 50 (31.6%), and 60 (38.0%) in the central IV, IC, and peripheral IV arms, respectively. Peripheral IV epinephrine administration route was associated with lower odds of achieving return of spontaneous circulation (ROSC, odds ratio = 0.14, 95% confidence interval = 0.05-0.36, p < 0.0001) compared with central IV and IC administration. (There was no difference between central IV and IC routes; p = 0.9343.) The odds of stent thrombosis were significantly higher with the IC route (IC vs. peripheral IV OR = 4.6, 95% CI = 1.5-14.3, p = 0.0094; IC vs. central IV OR = 6.0, 95% CI = 1.9-19.2, p = 0.0025). Post-ROSC neurologic outcomes were better for central IV and IC routes when compared with peripheral IV.

CONCLUSION: Epinephrine administration via central IV and IC routes was associated with a higher rate of ROSC and better neurologic outcomes compared with peripheral IV administration. IC administration was associated with a higher risk of stent thrombosis. Trial registration This trial is registered at NCT05253937 .

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Aldujeli A, Haq A, Tecson KM, et al. A prospective observational study on impact of epinephrine administration route on acute myocardial infarction patients with cardiac arrest in the catheterization laboratory (iCPR study). Crit Care. 2022. PMID: 36539907. doi:10.1186/s13054-022-04275-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。